Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double-tracer positron emission tomography study

Annals of Neurology

Volumn 46, Issue 5, 1999, Pages 723-731

  Ouchi, Yasuomi ^a   Kanno, Toshihiko ^a   Okada, Hiroyuki ^b   Yoshikawa, Etsuji ^b   Futatsubashi, Masami ^b   Nobezawa, Shuji ^a   Torizuka, Tatsuo ^a   Sakamoto, Masanobu ^a  

^a HAMAMATSU MEDICAL CENTER   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; AGED; BRAIN; CARBON RADIOISOTOPES; CARRIER PROTEINS; CAUDATE NUCLEUS; CEREBELLUM; CEREBRAL CORTEX; COCAINE; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; RECEPTORS, DOPAMINE D1; REFERENCE VALUES; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032752306     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199911)46:5<723::AID-ANA7>3.0.CO;2-R     Document Type: Article

References (47)

1. German DC, Manaye K, Smith WK, et al. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-514
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
3. Aquilonius SM, Bergstrom K, Eckernas SA, et al. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand 1987;76:283-287
4. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298
5. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431
6. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884
7. Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542
8. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576
9. Cortes R, Camps M, Gueye B, et al. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 1989; 483:30-38
10. Rinne UK, Laihinen A, Rinne JO, et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59
11. Shinotoh H, Inoue O, Hirayama K, et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993;56:467-472
12. Sawle GV, Playford ED, Brooks DJ, et al. Asymmetrical presynaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism: diagnostic implications of the D2 receptor status. Brain 1993;116:853-867
13. Volkow ND, Wang GJ, Fowler JS, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998;44:143-147
14. Oades RD, Halliday GM. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res 1987; 434:117-165
15. Avoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 1980;30:1326-1330
16. Scatton B, Rouquier L, Javoy-Agid F, Agid Y. Dopamine deficiency in the cerebral cortex in Parkinson disease. Neurology 1982;32:1039-1040
17. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321-328
18. Ouchi Y, Nobezawa S, Okada H, et al. Glucose metabolism of the human hippocampal formation in the hippocampal long axis plane measured by PET. J Cereb Blood Flow Metab 1997; 17:5218 (Abstract)
19. Yamashita T, Uchida H, Okada H, et al. Development of a high resolution PET. IEEE Trans Nucl Sci 1990;37:594-599
20. Suhara T, Fukuda H, Inoue O, et al. Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 1991;103:41-45
21. Ouchi Y, Nobezawa S, Okada H, et al. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136-142
22. Mai JK, Assheuer J, Paxinos G. Atlas of the human brain. San Diego: Academic Press, 1997
23. Buchanan RW, Vladar K, Barta PE, Pearlson GD. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 1998;155:1049-1055
24. Backman L, Robins-Wahlin TB, Lundin A, et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997;120:2207-2217
25. 11C]WIN 35,428. Synapse 1993;15:130-142
26. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991;11:735-744
27. Palacios JM, Camps M, Cortes R, Probst A. Mapping dopamine receptors in the human brain. J Neural Transm Suppl 1988;27:227-235
28. Mintun MA, Raichle ME, Kilbourn MR, et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227
29. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747
30. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840
31. 11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 1998;50:152-156
32. Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985;69:223-230
33. Parent A. Cerebral cortex. In: Carpenter's human neuroanatomy. Baltimore: Williams and Wilkins, 1996:864-936
34. Porrino LJ, Goldman-Rakic PS. Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol 1982; 205:63-76
35. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985;35:1215-1218
36. Ernst M, Zametkin AJ, Matochik JA, et al. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18] fluorodopa positron emission tomographic study. J Neurosci 1998;18:5901-5907
37. Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988;86:291-306
38. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-723
39. 11C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44: 1325-1329
40. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-636
41. Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 1997;48:969-977
42. Fitzsimonds RM, Song HJ, Poo MM. Propagation of activity-dependent synaptic depression in simple neural networks. Nature 1997;388:439-448
43. Lavoie B, Smith Y, Parent A. Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J Comp Neurol 1989;289: 36-52
44. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-236
45. Colman H, Nabekura J, Lichtman JW. Alterations in synaptic strength preceding axon withdrawal. Science 1997;275:356-361
46. Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 1998; 51(Suppl 2):S13-S20
47. 123I-Iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556-561